Generate Investment Management Ltd Buys 15,352 Shares of Eli Lilly and Company $LLY

Generate Investment Management Ltd boosted its stake in Eli Lilly and Company (NYSE:LLY) by 23.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 81,813 shares of the company’s stock after buying an additional 15,352 shares during the quarter. Eli Lilly and Company makes up about 3.2% of Generate Investment Management Ltd’s holdings, making the stock its 7th biggest position. Generate Investment Management Ltd’s holdings in Eli Lilly and Company were worth $62,423,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of LLY. Laurel Wealth Advisors LLC boosted its position in Eli Lilly and Company by 78,621.2% during the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $8,827,714,000. Vanguard Group Inc. raised its stake in shares of Eli Lilly and Company by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Eli Lilly and Company by 106.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company’s stock worth $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. Finally, Franklin Resources Inc. lifted its holdings in shares of Eli Lilly and Company by 13.4% during the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock valued at $3,715,913,000 after buying an additional 564,736 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Leerink Partners restated an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, December 18th. BMO Capital Markets set a $1,200.00 price target on shares of Eli Lilly and Company in a research note on Thursday, December 4th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,200.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Bank of America decreased their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. Finally, Guggenheim restated a “buy” rating and set a $1,163.00 target price on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Four research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,155.36.

Eli Lilly and Company Stock Down 0.4%

LLY stock opened at $1,075.00 on Thursday. The stock has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.59, a price-to-earnings-growth ratio of 1.09 and a beta of 0.37. The company has a 50-day moving average of $1,003.00 and a two-hundred day moving average of $846.93. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The business had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period in the previous year, the company posted $1.18 earnings per share. The firm’s revenue for the quarter was up 53.9% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.